APA

Savès M., Raffi F., Clevenbergh P., Marchou B., Waldner-Combernoux A., Morlat P., Le Moing V., Rivière C., Chêne G. & Leport C. (20010215). Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. : Antimicrobial agents and chemotherapy.

Chicago

Savès M, Raffi F, Clevenbergh P, Marchou B, Waldner-Combernoux A, Morlat P, Le Moing V, Rivière C, Chêne G and Leport C. 20010215. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. : Antimicrobial agents and chemotherapy.

Harvard

Savès M., Raffi F., Clevenbergh P., Marchou B., Waldner-Combernoux A., Morlat P., Le Moing V., Rivière C., Chêne G. and Leport C. (20010215). Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. : Antimicrobial agents and chemotherapy.

MLA

Savès M, Raffi F, Clevenbergh P, Marchou B, Waldner-Combernoux A, Morlat P, Le Moing V, Rivière C, Chêne G and Leport C. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. : Antimicrobial agents and chemotherapy. 20010215.